<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 12, 1997
ALPHA 1 BIOMEDICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-15070 52-1253406
(State or other (Commission File (IRS Employer
jurisdiction of Number) Identification No.)
incorporation)
6707 Democracy Boulevard
Suite 111
Bethesda, MD 20817
(Address, including Zip Code, of principal executive offices)
Registrant's telephone number, including area code:
301-564-4400
<PAGE> 2
Item 5. Other Events
The Press Release dated March 12, 1997 for Alpha 1 Biomedicals, Inc.
attached as Exhibit 1 is incorporated by reference.
Item 7. Exhibits
(1) Press Release, dated March 12, 1997
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: March 12, 1997 ALPHA 1 BIOMEDICALS, INC.
By: /s/ R.J. Lanham
-----------------------
R.J. Lanham
Vice President &
Chief Financial Officer
<PAGE> 1
EXHIBIT 1
FOR IMMEDIATE RELEASE
CONTACT: R. J. Lanham
Vice President and
Chief Financial Officer
301-564-4400
ALPHA 1 BIOMEDICALS, INC.
CONCLUDES PRIVATE FINANCING AND FUNDS NEW STUDY
BETHESDA, MARYLAND, MARCH 12, 1997-- ALPHA 1 BIOMEDICALS, INC. (OTC Bulletin
Board:ALBM) today announced the closing of a private placement of four units
consisting of Common Stock and Class D Warrants from which the Company received
$200,000. Each unit consists of 500,000 Common Shares and 165,000 Class D
Warrants. The newly issued shares increase the total outstanding shares to
11,477,429. The proceeds of the offering will be used in part to initiate
preclinical animal studies at a major US university using the Company's
product, Thymosin beta 4, and to fund its operations.
Alpha 1 has exclusive rights to two recently issued US patents entitled "Method
of Treating Septic Shock Using Thymosin beta 4" (Patent 5,578,570 issued
November 26, 1996) and "Method of Treating Septic Shock by Preventing Actin
Polymerization" (Patent 5,593,964 issued January 14, 1997). The Company
intends to focus on the use of Thymosin beta 4 for the treatment of adult
respiratory distress syndrome (ARDS), a frequently lethal outcome of septic
shock.
The Company is continuing its efforts to identify sources of strategic
alliances or other partnership arrangements with entities interested in and
with resources to develop Thymosin beta 4, or other business transactions which
would allow the Company to generate resources to assure continuation of its
operations.
***/***
